Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Elephas Biosciences Secures $40M Series B-2 Funding to Advance Live Tumor Profiling Platform
Series BVenture Capital

Elephas Biosciences Secures $40M Series B-2 Funding to Advance Live Tumor Profiling Platform

•November 6, 2025
•Nov 6, 2025
0

Participants

Elephas

Elephas

company

ARCH Venture Partners

ARCH Venture Partners

investor

Sands Capital

Sands Capital

investor

State of Wisconsin Investment Board

State of Wisconsin Investment Board

investor

Venture Investors

Venture Investors

investor

Northpond Ventures

Northpond Ventures

investor

Private Equity International

Private Equity International

investor

Why It Matters

The capital infusion accelerates development and commercialization of a technology that could dramatically improve patient selection for immunotherapies, reducing costly trial-and‑error and expanding market adoption. Successful deployment would address a critical gap in oncology, potentially improving outcomes and lowering healthcare costs.

Deal Summary

Elephas Biosciences announced a $40 million Series B-2 round to scale its live tumor profiling technology for immunotherapy response prediction. Existing backers including Northpond Ventures, ARCH Venture Partners, the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital and Venture Investors Health Fund participated in the equity round.

0

Comments

Want to join the conversation?

Loading comments...